Lung Cancer
Volume 67, Issue 3 , Pages 290-295 , March 2010

Expression of melanoma-antigen-A (MAGE-A) in disseminated tumor cells in regional lymph nodes of patients with operable non-small cell lung cancer

  • Sebastian Dango

      Affiliations

    • Department of Thoracic Surgery, Albert-Ludwigs University Freiburg, 79106 Freiburg, Germany
    • Corresponding Author InformationCorresponding author at: Department of Thoracic Surgery, University Hospital Freiburg, Albert-Ludwigs University Freiburg, Hugstetter Strasse 55, 79106 Freiburg, Germany. Tel.: +49 761 2702457; fax: +49 761 2702499.
    • ,
  • Xiao Tao Wang

      Affiliations

    • Department of Thoracic Surgery, Albert-Ludwigs University Freiburg, 79106 Freiburg, Germany
    • ,
  • Monika Gold

      Affiliations

    • Department of Thoracic Surgery, Albert-Ludwigs University Freiburg, 79106 Freiburg, Germany
    • ,
  • Beatrix Cucuruz

      Affiliations

    • Department of Thoracic Surgery, Albert-Ludwigs University Freiburg, 79106 Freiburg, Germany
    • ,
  • Christoph A. Klein

      Affiliations

    • Department of Pathology, Division of Oncogenomics, University of Regensburg, 93053 Regensburg, Germany
    • ,
  • Bernward Passlick

      Affiliations

    • Department of Thoracic Surgery, Albert-Ludwigs University Freiburg, 79106 Freiburg, Germany
    • ,
  • Wulf Sienel

      Affiliations

    • Department of Thoracic Surgery, Albert-Ludwigs University Freiburg, 79106 Freiburg, Germany

Received 23 October 2008 ,Revised 9 March 2009 ,Accepted 20 April 2009.

References 

  1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71–96
  2. Winton T, Livingston R, Johnson D, Rigas J, Johnston M, Butts C, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med. 2005;352:2589–2597
  3. Douillard JY, Rosell R, De Lena M, Carpagnano F, Ramlau R, Gonzales-Larriba JL, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol. 2006;7:719–727
  4. Roselli M, Mariotti S, Ferroni P, Laudisi A, Mineo D, Pompeo E, et al. Postsurgical chemotherapy in stage IB nonsmall cell lung cancer: long-term survival in a randomized study. Int J Cancer. 2006;119:955–960
  5. Pantel K, Brakenhoff RH, Brandt B. Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat Rev Cancer. 2008;8:329–340
  6. Pantel K, Schlimok G, Braun S, Kutter D, Lindemann F, Schaller G, et al. Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. J Natl Cancer Inst. 1993;85:1419–1424
  7. Takahashi K, Shichijo S, Noguchi M, Hirohata M, Itoh K. Identification of MAGE-1 and MAGE-4 proteins in spermatogonia and primary spermatocytes of testis. Cancer Res. 1995;55:3478–3482
  8. Tomita Y, Kimura M, Tanikawa T, Nishiyama T, Morishita H, Takeda M, et al. Immunohistochemical detection of intercellular adhesion molecule-1 (ICAM-1) and major histocompatibility complex class I antigens in seminoma. J Urol. 1993;149:659–663
  9. Marchand M, van Baren N, Weynants P, Brichard V, Dreno B, Tessier MH, et al. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer. 1999;80:219–230
  10. Salgaller ML. The development of immunotherapies for non-small cell lung cancer. Expert Opin Biol Ther. 2002;2:265–278
  11. Van Der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, van den EB, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 1991;254:1643–1647
  12. Chomez P, De Backer O, Bertrand M, De Plaen E, Boon T, Lucas S. An overview of the MAGE gene family with the identification of all human members of the family. Cancer Res. 2001;61:5544–5551
  13. Ohman FK, Nordqvist K. The melanoma antigen genes—any clues to their functions in normal tissues?. Exp Cell Res. 2001;265:185–194
  14. Honda T, Tamura G, Waki T, Kawata S, Terashima M, Nishizuka S, et al. Demethylation of MAGE promoters during gastric cancer progression. Br J Cancer. 2004;90:838–843
  15. De Plaen E, Arden K, Traversari C, Gaforio JJ, Szikora JP, De Smet C, et al. Structure, chromosomal localization, and expression of 12 genes of the MAGE family. Immunogenetics. 1994;40:360–369
  16. Kocher T, Zheng M, Bolli M, Simon R, Forster T, Schultz-Thater E, et al. Prognostic relevance of MAGE-A4 tumor antigen expression in transitional cell carcinoma of the urinary bladder: a tissue microarray study. Int J Cancer. 2002;100:702–705
  17. Tian XX, Rai D, Li J, Zou C, Bai Y, Wazer D, et al. BRCA2 suppresses cell proliferation via stabilizing MAGE-D1. Cancer Res. 2005;65:4747–4753
  18. Melloni G, Ferreri AJ, Russo V, Gattinoni L, Arrigoni G, Ceresoli GL, et al. Prognostic significance of cancer-testis gene expression in resected non-small cell lung cancer patients. Oncol Rep. 2004;12:145–151
  19. De Smet C, Lurquin C, Lethe B, Martelange V, Boon T. DNA methylation is the primary silencing mechanism for a set of germ line- and tumor-specific genes with a CpG-rich promoter. Mol Cell Biol. 1999;19:7327–7335
  20. De Smet C, Loriot A, Boon T. Promoter-dependent mechanism leading to selective hypomethylation within the 5′ region of gene MAGE-A1 in tumor cells. Mol Cell Biol. 2004;24:4781–4790
  21. Mountain CF. Revisions in the international system for staging lung cancer. Chest. 1997;111:1710–1717
  22. Mountain CF, Dresler CM. Regional lymph node classification for lung cancer staging. Chest. 1997;111:1718–1723
  23. Ruud P, Fodstad O, Hovig E. Identification of a novel cytokeratin 19 pseudogene that may interfere with reverse transcriptase-polymerase chain reaction assays used to detect micrometastatic tumor cells. Int J Cancer. 1999;80:119–125
  24. Noguchi S, Aihara T, Motomura K, Inaji H, Imaoka S, Koyama H. Detection of breast cancer micrometastases in axillary lymph nodes by means of reverse transcriptase-polymerase chain reaction. Comparison between MUC1 mRNA and keratin 19 mRNA amplification. Am J Pathol. 1996;148:649–656
  25. Soong R, Beyser K, Basten O, Kalbe A, Rueschoff J, Tabiti K. Quantitative reverse transcription-polymerase chain reaction detection of cytokeratin 20 in noncolorectal lymph nodes. Clin Cancer Res. 2001;7:3423–3429
  26. Wang XT, Sienel W, Eggeling S, Ludwig C, Stoelben E, Mueller J, et al. Detection of disseminated tumor cells in mediastinoscopic lymph node biopsies and lymphadenectomy specimens of patients with NSCLC by quantitative RT-PCR. Eur J Cardiothorac Surg. 2005;28:26–32
  27. Pimpec-Barthes F, Danel C, Lacave R, Ricci S, Bry X, Lancelin F, et al. Association of CK19 mRNA detection of occult cancer cells in mediastinal lymph nodes in non-small cell lung carcinoma and high risk of early recurrence. Eur J Cancer. 2005;41:306–312
  28. Lugo TG, Braun S, Cote RJ, Pantel K, Rusch V. Detection and measurement of occult disease for the prognosis of solid tumors. J Clin Oncol. 2003;21:2609–2615
  29. Kwon S, Kang SH, Ro J, Jeon CH, Park JW, Lee ES. The melanoma antigen gene as a surveillance marker for the detection of circulating tumor cells in patients with breast carcinoma. Cancer. 2005;104:251–256
  30. Kufer P, Zippelius A, Lutterbuse R, Mecklenburg I, Enzmann T, Montag A, et al. Heterogeneous expression of MAGE-A genes in occult disseminated tumor cells: a novel multimarker reverse transcription-polymerase chain reaction for diagnosis of micrometastatic disease. Cancer Res. 2002;62:251–261
  31. Mecklenburg I, Stratakis DF, Huber RM, Haussinger K, Morresi-Hauf A, Riethmuller G, et al. Detection of melanoma antigen-A expression in sputum and bronchial lavage fluid of patients with lung cancer. Chest. 2004;125:164S–166S
  32. Jheon S, Hyun DS, Lee SC, Yoon GS, Jeon CH, Park JW, et al. Lung cancer detection by a RT-nested PCR using MAGE A1–6 common primers. Lung Cancer. 2004;43:29–37
  33. Passlick B, Izbicki JR, Kubuschok B, Thetter O, Pantel K. Detection of disseminated lung cancer cells in lymph nodes: impact on staging and prognosis. Ann Thorac Surg. 1996;61:177–183
  34. Kubuschok B, Passlick B, Izbicki JR, Thetter O, Pantel K. Disseminated tumor cells in lymph nodes as a determinant for survival in surgically resected non-small cell lung cancer. J Clin Oncol. 1999;17:19–24
  35. Gray JW. Evidence emerges for early metastasis and parallel evolution of primary and metastatic tumors. Cancer Cell. 2003;4:4–6
  36. Schmidt-Kittler O, Ragg T, Daskalakis A, Granzow M, Ahr A, Blankenstein TJ, et al. From latent disseminated cells to overt metastasis: genetic analysis of systemic breast cancer progression. Proc Natl Acad Sci USA. 2003;100:7737–7742
  37. Balic M, Lin H, Young L, Hawes D, Giuliano A, McNamara G, et al. Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clin Cancer Res. 2006;12:5615–5621
  38. Park JW, Kwon TK, Kim IH, Sohn SS, Kim YS, Kim CI, et al. A new strategy for the diagnosis of MAGE-expressing cancers. J Immunol Methods. 2002;266:79–86
  39. Scott WJ, Howington J, Feigenberg S, Movsas B, Pisters K. Treatment of non-small cell lung cancer stage I and stage II: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007;132:234S–242S
  40. Pignon JP, Tribodet H, Scagliotti GV, Douillard JY, Shepherd FA, Stephens RJ, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol. 2008;26:3552–3559
  41. Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med. 2004;350:351–360
  42. Strauss GM, Herndon JE, Maddaus MA, Johnstone DW, Johnson EA, Harpole DH, et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol. 2008;26:5043–5051
  43. Kruit WH, van Ojik HH, Brichard VG, Escudier B, Dorval T, Dreno B, et al. Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma. Int J Cancer. 2005;117:596–604
  44. van Baren N, Bonnet MC, Dreno B, Khammari A, Dorval T, Piperno-Neumann S, et al. Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells. J Clin Oncol. 2005;23:1–14
  45. Vansteenkiste J, Zielinski M, Linder A, Dahabre J, Esteban E, Malinowski W, et al. Final results of a multi-center, double-blind, randomized, placebo-controlled phase II study to assess the efficacy of MAGE-A3 immunotherapeutic as adjuvant therapy in stage IB/II non-small cell lung cancer (NSCLC). 2007 ASCO Annual Meeting Proceedings Part I. J Clin Oncol. 2007;25:7554

☆ Financial support: This work was supported by Deutsche Forschungsgemeinschaft (DFG KL 1233/1-1).

PII: S0169-5002(09)00252-9

doi: 10.1016/j.lungcan.2009.04.012

Lung Cancer
Volume 67, Issue 3 , Pages 290-295 , March 2010

Article Tools

* Image Usage & Resolution